Pulse Biosciences (Nasdaq:PLSE) announced today the appointment of Paul A. LaViolette, the co-chair of its board, as the company’s new Chief Executive Officer. LaViolette steps in for Burke T. Barrett, who resigned on December 6th after a tenure of just six months in the position, having been appointed in May 2024.
“We are excited to have Paul take on the CEO role,” expressed Pulse Biosciences’ co-chair, Robert W. Duggan. “Having closely collaborated with Paul, we have cultivated a strong partnership and found that our visions for the company’s direction are closely aligned. His extensive experience and connections in the medical technology sector are proven through years of leadership and innovation. Especially noteworthy is Paul’s capability in expanding global franchises in various clinical domains and promoting the use of new technologies, which now become an even greater asset to Pulse moving forward.”
About the New CEO of Pulse Biosciences, Paul LaViolette
LaViolette brings significant operational experience from global healthcare firms. As a managing partner at SV Health Investors, he took an active role in numerous companies in their portfolio and continues to participate on several boards. Prior to his ventures in investment, he held diverse executive roles at Boston Scientific, where he spent 15 years.
During his tenure at Boston Scientific, LaViolette held positions such as COO, Group President for Cardiovascular, President of Cardiology, President of Endosurgery, and President of International. Before joining Boston Scientific, he was President of Cardiology at CR Bard. He currently serves on the boards of Edwards and is Chair of the Innovation Advisory Board at Mass General Brigham.
LaViolette assumes the CEO role at Pulse Biosciences as the company makes strides with its pulsed field ablation (PFA) technology. Based in Hayward, California, Pulse Biosciences uses its CellFX nanosecond pulsed field ablation (nsPFA) technique along with a percutaneous electrode system, receiving FDA clearance earlier this year. The technology aids in the ablation of soft tissue during percutaneous and intraoperative surgical procedures.
“I am convinced that nano-PFA represents a significant advancement in medical technology, with the potential to greatly enhance healthcare for many patients and providers,” stated LaViolette. “The skilled team, innovative solutions, and development pipeline at Pulse drew me to the company. Having collaborated with Bob and the entire team, I am eager to embrace this role and propel the company’s future successes.”